Type 2 inflammation is the underlying cause of CRSwNP in 80% of patients. CRSwNP is predominantly characterized by Type 2 inflammation of the nose and paranasal sinuses. DUPIXENT blocks 2 key sources of type 2 inflammation and shrinks nasal polyps and reduces the need for surgery.